History

KPV grew out of decades of work on alpha-MSH's anti-inflammatory biology, led largely by James M. Lipton's group. The pivotal finding that the C-terminal fragment alone retains anti-inflammatory activity was reported by Hiltz and Lipton in 1989. Getting and colleagues dissected its receptor-independent action in 2003, and two 2008 papers established a PepT1 transport plus NF-kappaB mechanism with reproducible efficacy in mouse colitis. Work since then has stayed preclinical, focused on skin, wounds, and gut-targeted drug delivery. No human trials have followed, yet KPV entered the regulatory spotlight through the FDA's peptide-compounding review in 2023–2026.

KPV is one of the more scientifically interesting peptides in the wellness market: a tiny fragment of a natural hormone that, in lab and animal studies, hits inflammation hard while sidestepping the parent hormone’s other effects. The catch is the same one that follows most gray-market peptides — there are no human trials.

What it is

KPV is a linear tripeptide: three amino acids, lysine-proline-valine, strung together. That sequence is the C-terminal tail (residues 11 to 13) of alpha-melanocyte-stimulating hormone (alpha-MSH), a 13-amino-acid melanocortin peptide your body makes from a larger precursor protein called POMC.

What makes KPV notable is what it leaves out. Alpha-MSH’s pigment-darkening and receptor-binding activity lives in a different part of the molecule (the His-Phe-Arg-Trp motif). KPV does not contain that motif, yet researchers found it keeps most of alpha-MSH’s anti-inflammatory punch. In other words, it appears to separate the “calm inflammation” function from the “change skin color” function.

It is sold as “KPV (free base)” or “KPV acetate” through gray-market vendors as a research chemical. It is not a dietary supplement and not an approved drug.

The claims

In legitimate research, KPV has been studied for intestinal inflammation and inflammatory bowel disease (colitis), skin inflammation such as contact dermatitis, wound healing, and general suppression of NF-kappaB-driven inflammation. It has also been explored as cargo for gut-targeted drug-delivery systems.

The marketing goes much further. Vendor and clinic pages pitch KPV for “gut healing” and “leaky gut repair,” skin and anti-aging benefits, mast-cell stabilization, allergy and histamine control, antimicrobial wound care, and systemic anti-inflammatory recovery. Some sites describe it as a melanocortin (MC1R or MC3R) receptor agonist. That framing overstates the science: the primary literature on KPV’s gut effects emphasizes a receptor-independent mechanism, not receptor activation. Worth flagging too: most consumer-facing “evidence” pages are published by sellers, compounding clinics, or peptide-vendor blogs, not independent sources.

The evidence

There are no published human trials of KPV. No registered ClinicalTrials.gov studies and no peer-reviewed human efficacy or safety data exist for any route — oral, injected, or topical. Every claim about what KPV does in people is inferred from animal and cell-culture work.

That preclinical work, however, is genuinely substantial and spans about two decades.

The mechanistic milestones came in 2008. Dalmasso and colleagues (Gastroenterology) showed that KPV is carried into intestinal and immune cells by a transporter called PepT1 — which is more active in the inflamed colon — and that at nanomolar concentrations (around 10 nM in cell studies) it shuts down NF-kappaB and MAP-kinase signaling and reduces pro-inflammatory cytokines. Oral KPV reduced colitis severity in two different mouse models. The same year, Kannengiesser and colleagues (Inflammatory Bowel Disease) reported that KPV reduced inflammatory cell infiltration and tissue damage, improved weight recovery, and rescued mice lacking the melanocortin-1 receptor from fatal colitis — strong evidence that the effect does not depend on that receptor.

Earlier, Getting and colleagues (Journal of Pharmacology and Experimental Therapeutics, 2003) had shown KPV reduced immune-cell accumulation in mouse peritonitis models, behaved differently from core MSH peptides, and stayed active in mice with nonfunctional MC1R — pointing toward an effect driven by interleukin-1-beta inhibition rather than melanocortin receptors. A 2010 review by Brzoska and colleagues summarized the central finding that KPV retains anti-inflammatory activity without the receptor-binding motif. The whole line of research traces back to Hiltz and Lipton in 1989, the first demonstration that the C-terminal tripeptide region carries anti-inflammatory activity on its own.

More recent work has been about formulation rather than new clinical use — for example, hyaluronic-acid-coated nanoparticles loaded with KPV for oral delivery to the inflamed gut (Xiao and colleagues, 2017), and a study of getting KPV across microporated human skin by iontophoresis (Pawar and colleagues, 2017). The latter is a delivery and permeation experiment, not a test of whether KPV treats anything in people.

A few honest caveats about the animal data: the colitis models are chemically induced and are imperfect stand-ins for human IBD; the endpoints are largely histologic; and the work clusters around a handful of academic groups. What is missing is everything you would need to judge human use — pharmacokinetics, dose-finding, controlled efficacy and safety data, oral stability in humans, and long-term toxicology.

Safety and side effects

Published human safety data is essentially nonexistent. There is no controlled human safety dataset for KPV by any route.

In rodent studies, KPV was generally well tolerated, with anti-inflammatory benefit and no obvious organ toxicity at the doses tested — but those were efficacy studies, not formal toxicology, and were not designed to catch rare or long-term harms.

Be skeptical of precise-sounding side-effect numbers. Some vendor and clinic pages cite figures like “injection-site reactions in 8 to 12 percent” or “nausea in 3 to 5 percent.” These have no identifiable peer-reviewed human source and should not be treated as real data. The honest statement is that human safety is unknown. On top of that, gray-market product carries the usual unregulated-peptide risks: questionable purity and sterility, possible endotoxin contamination, and mislabeling.

Legal and regulatory status

A few separate facts get blurred together here, so take them one at a time.

KPV is not approved by the FDA for any use, and it is not a recognized dietary ingredient. It is sold gray-market as a research chemical.

It currently sits in the FDA’s 503A Category 2 — bulk drug substances with insufficient safety data, which are not eligible for the enforcement discretion that would let compounding pharmacies make them. That categorization traces to the FDA’s September 2023 action on nominated peptides, not to anything in 2026.

In April 2026, the FDA published a Federal Register notice (docket FDA-2025-N-6895) scheduling a Pharmacy Compounding Advisory Committee meeting for July 23–24, 2026. KPV is on the July 23 agenda alongside BPC-157, TB-500, and MOTS-C. Two things matter here: the committee’s recommendations are non-binding, and being on the agenda does not authorize compounding or imply approval. Any move to permit compounding would still require formal rulemaking. (This section is current as of June 2026 and is a moving target.)

No marketing authorization for KPV has been identified in any major jurisdiction abroad.

On anti-doping: KPV is not a named substance on the WADA Prohibited List for 2025 or 2026. It does not activate melanocortin receptors and has no documented performance-enhancing effect. That said, absence from the named list is not absolute clearance, given WADA’s catch-all language covering substances of similar structure or biological effect.

Bottom line

KPV has an unusually clean scientific story for a gray-market peptide: a well-characterized mechanism, reproducible anti-inflammatory effects in animals, and a clear rationale for why it might calm inflammation without alpha-MSH’s other actions. But “promising in mice” is not “proven in people.” There are no human trials, no human safety data, and no approved product. The marketing claims about gut healing, anti-aging, and recovery run far ahead of the evidence. Treat KPV as an interesting hypothesis, not an established treatment. This is not medical advice.

Evidence grade: Animal only.

KPV: A Promising Anti-Inflammatory Tripeptide With No Human Trials